Professional
Added to YB: 2024-02-29
Pitch date: 2024-02-22
AZN [bullish]
AstraZeneca PLC
+25.95%
current return
Author Info
No bio for this author
Company Info
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Market Cap
GBP 243.1B
Pitch Price
GBP 95.68
Price Target
80.00 (-34%)
Dividend
2.07%
EV/EBITDA
13.33
P/E
23.46
EV/Sales
4.41
Sector
Pharmaceuticals
Category
growth
AstraZeneca PLC: BUY on numerous product approvals
AZN: Argus Buy rating. Robust growth via new approvals (Tagrisso NSCLC, Dato-DXd NSCLC, Enhertu HER2+ tumors pending, Voydeya PNH in Japan, Beyfortus RSV in China, Wainua hATTR-PN) & acquisitions (Icosavax RSV vaccine Ph3, Gracell cell therapies cancer/SLE, Eccogene obesity/T2D deal). Strong Q4 adj EPS growth, 2024 low double-digit to teens % rev growth expected. $5.96B cash, 42% debt/capital, 2.3% div yield. $4.20 2024 EPS est (-16%), $80 PT for 25% total return. Risks: development & regulatory.
Read full article (7 min)